PFE · 10-Q · 2026Q2 · Full report

Impairment Charges

PFIZER INC · 2026-08-04 · Importance 90 · Surprise 100 · Matches filing data

Pfizer recognized $4.325 billion of certain asset impairments in second-quarter and first-half 2026 results. The impairment charge reduced GAAP net income attributable to Pfizer common shareholders by $4.325 billion and was excluded from adjusted income. The comparable 2025 asset impairment amounts were $93 million for the second quarter and $317 million for the first six months.

Key facts

• Other (income)/deductions—net unfavorable change of $3.0 billion in Q2 2026 and $2.9 billion for the first six months of 2026, primarily driven by intangible asset impairment charges, charges for certain legal matters, and increases in fair value of contingent consideration liabilities, partially offset by a net gain from sale of prior ViiV investment. source
• Certain asset impairments recognized in other (income)/deductions—net for the three months ended June 28, 2026: $(4,325) million (pre-tax), with an offsetting $4,325 million in net income adjustments. source
• Pfizer discloses the risk of an impairment charge related to intangible assets, goodwill or equity-method investments. source

Impact estimates